17/03/2026
The Semaglutide patent wall is cracking in 2026. Is your manufacturing facility ready for the biosimilar wave? The biggest bottleneck in the GLP-1 market right now is injection pen assembly capacity.
Take a quick look at DROFEN MACHINERY's fully automated Insulin and GLP-1 Pen Final Assembly Line in action. We engineer high-speed, zero-defect production systems designed to help pharmaceutical companies scale up rapidly and capture market share.
"Make customers great again" — The DROFEN TEAM is dedicated to delivering world-class engineering for the pharmaceutical packaging industry.
🔹 Key Advantages of Our Turnkey Assembly Solution:
• High-speed continuous robotic assembly for maximum throughput
• 100% In-line vision inspection (IPC) ensuring zero-defect manufacturing
• Modular architecture adaptable for various disposable and reusable auto-injectors
• Quick changeover design for operational flexibility
• Complete turnkey CDMO service from initial design to FAT/SAT
🔹 Regulatory Compliance:
• Fully compliant with GAMP5 guidelines
• FDA 21 CFR Part 11 ready for electronic records
• EU GMP Annex 11 compliant
• Built to global cGMP pharmaceutical manufacturing standards
Don't let production limits hold you back in the booming weight-loss and diabetes care market. Invest in a proven assembly solution that’s already running in facilities worldwide.
💬 Ready to expand your capacity? Contact our engineering team today:
📧 Email: info@drofen-pharma.com
📱 WhatsApp: +86 18930046646
🌐 Website: https://www.drofen-pharma.com/showroom/insulin-injection-pen-auto-assembly-machine/
